Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 ...

And that was the last time I tried. When we were eight years old, we had severe scoliosis which caused us to have to get a spinal fusion. Unfortunately, one of the bad things about it is it ...

The FDA has accepted for Priority Review the BLA for apitegromab for the improvement of motor function in patients with spinal muscular atrophy.

Spinal muscular atrophy (SMA) is a group of genetic disorders that causes a loss of motor nerve cells and muscle atrophy. There are five types of SMA relating to age of onset and symptom severity.

—Sleep-disordered breathing occurs frequently in patients with spinal muscular atrophy and can be obstructive or non-obstructive, with those diagnosed with non-obstructive SDB having worse ...

Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

In a groundbreaking pilot study, researchers have found evidence that spinal cord stimulation could potentially benefit individuals with neurodegenerative diseases like spinal muscular atrophy (SMA).

for apitegromab for the improvement of motor function in patients with spinal muscular atrophy (SMA). Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and ...